Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

40.11 +0.50 (+1.26%)
Streaming Delayed Price Updated: 10:52 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 80,009
Open 39.90
Bid (Size) 39.95 (4)
Ask (Size) 40.08 (1)
Prev. Close 39.61
Today's Range 39.46 - 40.48
52wk Range 36.56 - 67.66
Shares Outstanding 48,901,965
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
Top 2 Small Cap Healthcare Stocks to Buy Before Rate Cuts
These 2 small cap healthcare stocks could boom on a new sector breakout, Wall Street analysts see up to double-digit upside in each 
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates

Performance

YTD
-35.61%
-35.61%
1 Month
-0.84%
-0.84%
3 Month
-0.15%
-0.15%
6 Month
-28.27%
-28.27%
1 Year
-33.90%
-33.90%

More News

Read More
Why the growth investor may take a look at NASDAQ:AMPH.
Via Chartmill
Amphastar Announces Additional $50 Million Increase to its Share Buyback Program
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
Via ACCESSWIRE
Exploring NASDAQ:AMPH's growth characteristics.
Via Chartmill
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2024
Via ACCESSWIRE
NASDAQ:AMPH, an undervalued stock with good fundamentals.
Via Chartmill
Amphastar Receives FDA Approval for Albuterol Sulfate Inhalation Aerosol
Via ACCESSWIRE
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
Via ACCESSWIRE
AMPH Stock Earnings: Amphastar Pharma Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Federal Trade Commission Targets 'Junk Patent Listings' For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2023
Via ACCESSWIRE
Delving into NASDAQ:AMPH's Growth Prospects.
Via Chartmill
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Via ACCESSWIRE
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
Via Benzinga
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
Via ACCESSWIRE
Earnings Outlook For Amphastar Pharma
Via Benzinga
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Via Chartmill
Is NASDAQ:AMPH a Fit for Growth Investing Strategies?
Via Chartmill
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2024
Via ACCESSWIRE
CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+
Via Investor's Business Daily
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.